Tuesday, November 28, 2017

Medeor Therapeutics Finds $57M

San Mateo-based Medeor Therapeutics, a company which is developing cellular therapies for aid in organ transplants, starting with kidney transplants, has raised $57M in a Series B funding, according to the company. The funding was led by RA Capital Management, and also included Sofinnova Ventures, 6 Dimensions Capital, Vivo Capital and WuXi Healthcare Ventures. RA Capital's Peter Kolchinsky, and Sofinnova's Anand Mehra both join the company's board with the funding. Medero's technology is based on research out of Stanford University, and is focused on minimizing or eliminating chronic anti-rejection, immunosuppressive drug regimens used by new recipients of living donor transplants. More information »